Wednesday, December 13, 2017

MissionIRNewsBreaks – Pressure BioSciences, Inc. (PBIO) Acquires All Assets of BaroFold, Inc.

Pressure BioSciences (OTCQB: PBIO) today reported the acquisition of all assets of BaroFold, Inc. The assets acquired include all patents, equipment, and intellectual property relating to BaroFold’s PreEMT™ high-pressure protein refolding technology. A total of eight issued patents and several pending significantly enhances PBIO’s hold of intellectual property in high-pressure technologies. “In addition to the expected increase in revenue from instrument and consumable sales to customers developing biopharmaceutical manufacturing applications with the PreEMT technology, we expect the BaroFold acquisition to have positive effects on our services revenue as well. In this regard, we plan to continue the biologics contract research services program previously provided by Barofold. This entails extensive revenue-generating studies on the advantages of high-pressure processing in the manufacture of biopharmaceutical products using the patented PreEMT technology. We will also offer manufacturing-scale licenses to biopharmaceutical companies ready to take advantage of the PreEMT technology for more efficient production of their high-quality biological products. We believe such licenses have the potential to generate millions of dollars annually in royalty revenue,” Pressure Biosciences president and CEO Richard T. Schumacher stated in the news release.

To read the full press release, visit http://dtn.fm/3LsbX

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. PBI’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug development and design, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Major new focal market opportunities are emerging in the use of the company’s patented, scalable, high-efficiency Ultra Shear Technology (“UST”) to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water), and to prepare higher quality, homogenized, extended shelf-life or room temperature stable, low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html